Experienced finance leader Paul Herendeen has been named executive vice president and chief financial officer (CFO) of Canadian drugmaker Valeant. 23 August 2016
Following the death of Giovanni Recordati, who was chairman and chief executive of the largely family-owned Italian drugmaker Recordati, the company’s board of directors has decided to appoint Alberto Recordati, a brother of Giovanni, as chairman and Andrea Recordati as vice chairman and chief executive. 17 August 2016
Indian drugmaker Cipla has appointed Umang Vohra as its new managing director and global chief executive to replace the outgoing Subhanu Saxena. 16 August 2016
Italian drugmaker Recordati announced today that its chairman and chief executive, Giovanni Recordati, aged 66, has passed away following a long illness. 16 August 2016
The chairman of the management board of German drugmaker Stada Arzneimittel has resigned due to personal circumstances, the company has announced. 16 August 2016
US clinical-stage biotech firm Sorrento Therapeutics has appointed Jerome Zeldis, former chief medical officer of Celgene Corp, as its CMO and president of clinical development. 15 August 2016
US pharma major Eli Lilly has announced that Joshua Smiley will be appointed to the post of senior vice president, finance, and treasurer effective October 1. 11 August 2016
A series of changes to the executive management team have been announced by Canada-based Valeant Pharmaceuticals and its new chief executive Joe Papa. 9 August 2016
Privately-held UK biotech Chronos Therapeutics has appointed experienced pharma duo Fraser Murray and Timothy Schulz-Utermoehl as vice presidents of pre-clinical development. 4 August 2016
US pharma major Eli Lilly is to have an new president and chief executive effective next year, as incumbent John Lechleiter is to retire at the end of 2016, the company has announced. 27 July 2016
George Scangos is to step down as the chief executive of US biotech major Biogen, it was announced on Thursday, when the company also revealed results for 2016’s second quarter which exceeded analysts’ expectations. 21 July 2016
Ireland-incorporated Perrigo has announced that Douglas Boothe, the general manager of its Rx Pharmaceuticals segment, is leaving the company. 21 July 2016
The pharmaceutical industry’s use of directors from outside the sector has fallen from 40% to 26% in the last five years, research from executive search firm DHR International shows. 12 July 2016
Taro Pharmaceutical Industries announced today that its chief executive, Kalyanasundaram (Kal) Sundaram, has informed Taro’s board of directors of his intention to step down as CEO by the end of the current calendar year. 7 July 2016
China-based biopharma firm CStone Pharmaceuticals says it has closed its Series A round of $150 million dollars financing (about 975 million renminbi). 4 July 2016
USA-based generic pharmaceutical company G & W Laboratories has announced the appointment of Jay Galeota to the position of president and chief operating officer. 30 June 2016
Edward Jensen, the new chief operating officer at US-based Blueprint Bio, has described his excitement at being part of "arguably the most groundbreaking" venture in health care. 27 June 2016
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024
Nxera Pharma has entered a new commercial partnership agreement with fellow Japanese drugmaker Shionogi regarding the distribution and sales for Quviviq (daridorexant 25 and 50mg) in Japan. 1 October 2024
AstronauTx, a biotech developing novel treatments for Alzheimer's disease and other neurodegenerative disorders, has announced the appointment of Jane Rhodes as chief executive officer. 1 October 2024
Privately-held German pain specialist Grünenthal has appointed Jan Adams its new chief commercial officer (CCO) and a member of the corporate executive board. 30 September 2024
USA-based engineered regulatory T cells (Tregs) company GentiBio today announced the appointment of Dr Mark Bach as chief medical officer. 30 September 2024
Acadia Pharmaceuticals has appointed Catherine Owen Adams to succeed Steve Davis as chief executive (CEO) and a member of its board of directors. 28 September 2024
Recently-created by US biotech incubator Flagship Pioneering, Abiologics has announced the appointment of Maria-Chiara Magnone as its chief scientific officer. 26 September 2024
German privately-held biotech ARTCLINE Bio-Therapies today announced the appointment of Dirk Hessel as additional managing director of the company. 23 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US contract development and manufacturing organization (CDMO) BioCentriq has appointed Syed Husain as its new chief executive (CEO), and as a member of the board of directors. 19 September 2024
Structure Therapeutics, a specialist in small molecule treatments for metabolic and pulmonary diseases, has announced key leadership appointments. 18 September 2024
Californian biopharma 89bio, a company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, has announced an important appointment. 17 September 2024
British biotech IMU Biosciences has announced key changes to its leadership team as it looks to grow in the field of precision medicine. 17 September 2024
Ohio, USA-based Trailhead Biosystems has appointed Josh Snow as its new chief commercial officer, as the company moves to expand its presence in the commercial market with its iPSC-derived human cell products. 16 September 2024
Under pressure from certain shareholders, autoimmune diseases specialist Aurinia Pharmaceuticals on Friday said it has restructured its board of directors. 14 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024